Search results
Showing 1 to 7 of 7 results for relugolix/estradiol/norethisterone acetate
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
Relugolix–estradiol–norethisterone acetate for treating pain associated with endometriosis [ID3982]
In development [GID-TA10873] Expected publication date: TBC
Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]
In development [GID-TA11131] Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 22 April 2024.
September 2000 TA032 Multiple sclerosis - beta interferon and glatiramer acetate 26 November 2001 TA218 Myelodysplastic syndrome -...
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Around 4,500 women with uterine fibroids will be eligible for a new oral treatment after NICE recommended relugolix with estradiol and norethisterone acetate (also called Ryeqo and made by Gedeon Ritcher UK) in final draft guidance.